X
Xiaobing Lv
Publications - 6
Citations - 460
Xiaobing Lv is an academic researcher. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 4, co-authored 4 publications receiving 282 citations.
Papers
More filters
Journal ArticleDOI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller,Lemieux Rene M,Erin Artin,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Giovanni Cianchetta,Zhenwei Cai,Ding Zhou,Cui Dawei,Ping Chen,Kimberly Straley,Erica Tobin,Fang Wang,Muriel D. David,Virginie Penard-Lacronique,Cyril Quivoron,Véronique Saada,Stéphane de Botton,Stefan Gross,Lenny Dang,Hua Yang,Luke Utley,Yue Chen,Hyeryun Kim,Shengfang Jin,Zhiwei Gu,Gui Yao,Zhiyong Luo,Xiaobing Lv,Cheng Fang,Liping Yan,Andrew J. Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Katharine E. Yen +36 more
TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.
Journal ArticleDOI
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Zenon D. Konteatis,Erin Artin,Brandon Nicolay,Kimberly Straley,Anil K. Padyana,Lei Jin,Yue Chen,Rohini Narayaraswamy,Shuilong Tong,Feng Wang,Ding Zhou,Cui Dawei,Zhenwei Cai,Zhiyong Luo,Cheng Fang,Huachun Tang,Xiaobing Lv,Raj Nagaraja,Hua Yang,Shinsan M. Su,Zhihua Sui,Lenny Dang,Katharine E. Yen,Janeta Popovici-Muller,Paolo Codega,Carl Campos,Ingo K. Mellinghoff,Scott A. Biller +27 more
TL;DR: Vorasidenib represents a novel dual mIDH1/2 inhibitor that penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopicglioma mouse model.
Journal ArticleDOI
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency
Charles Kung,Jeff Hixon,Penelope A. Kosinski,Giovanni Cianchetta,Gavin Histen,Yue Chen,Collin Hill,Stefan Gross,Yaguang Si,Kendall Johnson,Byron DeLaBarre,Zhiyong Luo,Zhiwei Gu,Gui Yao,Huachun Tang,Cheng Fang,Yingxia Xu,Xiaobing Lv,Scott A. Biller,Shin-San Michael Su,Hua Yang,Janeta Popovici-Muller,Francesco G. Salituro,Lee Silverman,Lenny Dang +24 more
TL;DR: It is demonstrated that AG-348 can increase the activity of wild-type and mutant PK enzymes in biochemical assays and in patient red blood cells treated ex vivo, illustrating the potential for AG- 348 to restore the glycolytic pathway activity in patients with PK deficiency and ultimately lead to clinical benefit.
ComponentDOI
Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase.
Anil K. Padyana,Stefan Gross,Lei Jin,Giovanni Cianchetta,Rohini Narayanaswamy,Feng Wang,Rui Wang,Cheng Fang,Xiaobing Lv,Scott A. Biller,Lenny Dang,Christopher E. Mahoney,Nelamangala Nagaraja,David Pirman,Zhihua Sui,Janeta Popovici-Muller,Gromoslaw A. Smolen +16 more
TL;DR: The first three-dimensional high-resolution crystal structures of the human SQLE catalytic domain alone and bound with small molecule inhibitors are presented, which will facilitate the development of next-generation SQLE inhibitors.
Journal ArticleDOI
Abstract 476: ABM-1310 has significant improved BBB-penetration and intracranial tumor growth inhibition compared to FDA approved BRAF inhibitors
TL;DR: Chen et al. as mentioned in this paper proposed ABM-1310, a small-molecule BRAF inhibitor designed to treat primary CNS tumors or advanced cancer patients with BRAFv600 mutation, with or without brain metastasis.